Overview
Tirzepatide's twin-receptor mechanism — simultaneously engaging both GLP-1 and GIP receptors — makes it one of the most pharmacologically interesting compounds in current metabolic research, and the 40mg vial gives research teams the volume to conduct comprehensive studies.
Tirzepatide 40mg is planned for the Indonesia catalogue. Register for availability updates.
Key Research Areas
High-Volume Laboratory Research
The 40mg vial provides sufficient compound for extended research programmes, multi-arm studies, or shared use across research team members.
GLP-1 and GIP Dual-Receptor Studies
The compound's unique dual mechanism continues to make it a focus of receptor pharmacology research globally, particularly in metabolic and endocrine research.
Longitudinal Metabolic Studies
Suitable for studies requiring consistent compound access over extended timeframes without the need for repeat ordering.
Cellular Signalling Research
Used in pancreatic, hepatic, and adipose tissue cell line models to investigate downstream signalling cascades from dual incretin receptor activation.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 40mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Research use | In vitro / laboratory use only |
| Availability | Launching Soon |
Launching-soon batch report
Batch TIRZ40-2607-01 · Measured content 41.71mg · Purity 99.856% · Analysed by Janoshik Analytical on 29 July 2026.
Tirzepatide 40mg is launching soon and is not represented as current Indonesia stock.
Verify task #210011 directly with Janoshik →